SEC Tracker
Get the app

Palvella Therapeutics PVLA

Palvella Therapeutics gets FDA Priority Review for QTORIN

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. FDA accepted NDA for QTORIN 3.9% gel
  2. Priority Review granted with Feb 28, 2027 target date

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Palvella Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Esperion Therapeutics ESPR public float $198M, Jun 30, 2025
  2. Editas Medicine EDIT public float $191M, Jun 30, 2025
  3. Rezolute RZLT public float $204M, Dec 31, 2025
  4. Cardiff Oncology CRDF public float $205M, Jun 30, 2025
  5. Silence Therapeutics SLN public float $206M, Jun 30, 2025